PowerUp Acquisition announces definitive merger with Aspire Biopharma at $316M pre-money valuation

Aspire Biopharma Holdings, Inc.

Pre-money equity value of Aspire approximately $316 million.
Combined company to be named 'Aspire Biopharma Holdings, Inc.' and list on Nasdaq under 'ASPH'.
Existing Aspire shareholders expected to retain majority ownership after closing.
Expected closing end of Q4 2024 or beginning of Q1 2025; subject to regulatory and stockholder approvals.
Aspire's lead product Instaprin (soluble aspirin) targeting 505(b)(2) NDA with FDA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.